

# EFFECTIVENESS AND SAFETY OF OFF-LABEL VERTEPORFIN PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY

JULIÁN MARTÍN, R; SERRANO VICENTE, MC; VICENTE ITURBE, C; BELLO CALVO, R;

ABAD SAZATORNIL, MR

✉ rjulianm@salud.aragon.es



4CPS-032

Pharmacy Department. Miguel Servet University Hospital. Zaragoza, Spain.



## BACKGROUND AND IMPORTANCE

Chronic central serous chorioretinopathy (cCSC) can lead to persistent subretinal fluid and progressive visual impairment. Off-label photodynamic therapy (PDT) with verteporfin is a potential treatment for refractory cases, though real-world evidence remains limited.




## AIM AND OBJECTIVES

To evaluate the effectiveness and safety of off-label verteporfin PDT in patients with cCSC treated in a tertiary university hospital.



## RESULTS

- **Demographics:** 71% men, mean age  $58 \pm 11.6$  years
- **Visual outcomes:**



- **56.0%** of eyes showed clinical improvement in visual acuity. Anatomical success was achieved in the majority of eyes (**SRF reduction in n=15/21; NRD improvement in n=19/27 and PED improvement in n=9/13**).

## MATERIALS AND METHODS



- **Design:** Retrospective observational study (January 2021- March 2024).



- **Patients:** 50 eyes from 41 patients with cCSC.




- **Intervention:** Verteporfin PDT at a dose of 3 mg/m<sup>2</sup>.

- **Assessment:** Best-corrected visual acuity (BCVA) and anatomical outcomes (Neurosensory Retinal Detachment [NRD], Pigment Epithelium Detachment [PED], Subretinal Fluid [SRF]) were evaluated at baseline and 2 months post-PDT.



- **Safety:** Monitoring of adverse reactions (ARs).

## % of Eyes with Anatomical Improvement



**Safety:** Adverse reactions occurred in **3 patients (6%)**, presenting as secondary choroidal neovascularization. No systemic adverse events were reported.



## CONCLUSION AND RELEVANCE



Off-label verteporfin PDT **demonstrated statistically significant effectiveness** in patients with cCSC, leading to **significant improvements in BCVA and anatomical outcomes**. A majority of eyes with neurosensory retinal detachment, pigment epithelium detachment, or subretinal fluid showed clinical improvement, **with few reported ARs**. These results support verteporfin PDT as a **valuable therapeutic option to stabilize and improve vision in patients with cCSC**.